Lion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target by Oppenheimer Holdings, Inc. Analysts

Lion Biotechnologies, Inc. (NASDAQ:IOVA) has been given a $13.00 price objective by analysts at Oppenheimer Holdings, Inc. in a research report issued on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price target indicates a potential upside of 78.08% from the stock’s current price.

IOVA has been the subject of several other reports. Cowen and Company reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Saturday, May 20th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Lion Biotechnologies in a report on Wednesday, August 16th. Jefferies Group LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Lion Biotechnologies in a report on Tuesday, September 5th. Zacks Investment Research downgraded Lion Biotechnologies from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Finally, FBR & Co reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Thursday, May 18th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Lion Biotechnologies presently has an average rating of “Buy” and an average price target of $13.88.

Lion Biotechnologies (NASDAQ:IOVA) traded up 1.712% on Monday, hitting $7.425. The stock had a trading volume of 195,274 shares. The company’s market cap is $465.45 million. The firm’s 50-day moving average is $5.61 and its 200-day moving average is $6.43. Lion Biotechnologies has a 52-week low of $4.45 and a 52-week high of $8.61.

COPYRIGHT VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://sportsperspectives.com/2017/09/11/lion-biotechnologies-inc-iova-given-a-13-00-price-target-by-oppenheimer-holdings-inc-analysts.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. acquired a new stake in Lion Biotechnologies in the 2nd quarter valued at $19,013,000. AXA purchased a new position in Lion Biotechnologies in the 2nd quarter valued at about $4,989,000. Wells Fargo & Company MN purchased a new position in Lion Biotechnologies in the 2nd quarter valued at about $528,000. Franklin Resources Inc. purchased a new position in Lion Biotechnologies in the 2nd quarter valued at about $37,844,000. Finally, Atlantic Trust Group LLC purchased a new position in Lion Biotechnologies in the 2nd quarter valued at about $316,000. Hedge funds and other institutional investors own 76.00% of the company’s stock.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply